Hallmarks of cancer: Of all cancer cells, all the time?

Trends in Molecular Medicine

Volumn 18, Issue 9, 2012, Pages 509-515

  Floor, Sébastien L ^a   Dumont, Jacques E ^a   Maenhaut, Carine ^a   Raspe, Eric ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cells and of time; Dynamic heterogeneity of cancer tissue; Hallmarks; Oncogenic events; Signaling

Indexed keywords

CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL HETEROGENEITY; REVIEW; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84865589453     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.06.005     Document Type: Review

References (75)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Delys L., et al. Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 2007, 26:7894-7903.
4. Tomas G., et al. A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic. Oncogene 2012, 10.1038/onc.2011.626.
5. De Bock K., et al. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2011, 21:73-79.
6. Hendrix M.J., et al. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
7. Kuppers M., et al. Regulation of ERK1/2 activity upon contact inhibition in fibroblasts. Biochem. Biophys. Res. Commun. 2011, 406:483-487.
8. Royer C., Lu X. Epithelial cell polarity: a major gatekeeper against cancer?. Cell Death Differ. 2011, 18:1470-1477.
9. Dalerba P., et al. Cancer stem cells: models and concepts. Annu. Rev. Med. 2007, 58:267-284.
10. Maenhaut C., et al. Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis 2010, 31:149-158.
11. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
12. Gupta P.B., et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
13. Dalerba P., et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol. 2011, 29:1120-1127.
14. Malaise E.P., et al. The relationship between growth rate, labelling index and histological type of human solid tumours. Eur. J. Cancer 1973, 9:305-312.
15. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 2010, 1805:105-117.
16. Snijder B., Pelkmans L. Origins of regulated cell-to-cell variability. Nat. Rev. Mol. Cell Biol. 2011, 12:119-125.
17. Bertos N.R., Park M. Breast cancer - one term, many entities?. J. Clin. Invest. 2011, 121:3789-3796.
18. Huang S. Non-genetic heterogeneity of cells in development: more than just noise. Development 2009, 136:3853-3862.
19. Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010, 327:542-545.
20. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother. Oncol. 2009, 92:329-333.
21. Wu Y., Zhou B.P. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009, 8:3267-3273.
22. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
23. Floor S., et al. Cancer cells in epithelial-to-mesenchymal transition and tumor propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011, 30:4609-4621.
24. Zalzman M., et al. Zscan4 regulates telomere elongation and genomic stability in ES cells. Nature 2010, 464:858-863.
25. Suter D.M., et al. Mammalian genes are transcribed with widely different bursting kinetics. Science 2011, 332:472-474.
26. Peter I.S., Davidson E.H. A gene regulatory network controlling the embryonic specification of endoderm. Nature 2011, 474:635-639.
27. Mani S.A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
28. Pinho A.V., et al. p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle 2011, 10:1312-1321.
29. Chang C.J., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13:317-323.
30. Brady C.A., et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145:571-583.
31. Boone D.N., Hann S.R. The Myc-ARF-Egr1 pathway: unleashing the apoptotic power of c-Myc. Cell Cycle 2011, 10:2043-2044.
32. Rowland B.D., et al. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 2005, 7:1074-1082.
33. Maurer G., et al. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011, 30:3477-3488.
34. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 2011, 11:254-267.
35. Li G.W., Xie X.S. Central dogma at the single-molecule level in living cells. Nature 2011, 475:308-315.
36. Ortiz-Zapater E., et al. Key contribution of CPEB4-mediated translational control to cancer progression. Nat. Med. 2012, 18:83-90.
37. Zhang J., et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012, 481:329-334.
38. Barrero M.J., Izpisua Belmonte J.C. Regenerating the epigenome. EMBO Rep. 2011, 12:208-215.
39. Morroni M., et al. Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16801-16806.
40. Bumbea H., et al. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors - the first molecular targeted treatment. J. Med. Life 2010, 3:162-166.
41. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
42. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
43. Stephens P.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
44. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
45. Samavarchi-Tehrani P., et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010, 7:64-77.
46. Hebrant A., et al. Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp. Cell Res. 2007, 313:3276-3284.
47. Weinberg R.A. Twisted epithelial-mesenchymal transition blocks senescence. Nat. Cell Biol. 2008, 10:1021-1023.
48. van Staveren W.C., et al. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:413-418.
49. Haakensen V.D., et al. Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. BMC Cancer 2011, 11:332.
50. Iovino N., Cavalli G. Rolling ES cells down the Waddington landscape with Oct4 and Sox2. Cell 2011, 145:815-817.
51. Tian M., et al. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal. 2011, 23:951-962.
52. Lock R., Debnath J. Ras, autophagy and glycolysis. Cell Cycle 2011, 10:1516-1517.
53. Yu L., Hales C.A. Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice. BMC Cancer 2011, 11:331.
54. Johnson D.G., Degregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr. Mol. Med. 2006, 6:731-738.
55. Wise D.R., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18782-18787.
56. Serrano M. Shifting senescence into quiescence by turning up p53. Cell Cycle 2010, 9:4256-4257.
57. Lisanti M.P., et al. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs " fertilizer" . Cell Cycle 2011, 10:2440-2449.
58. Kominsky D.J., et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin. Cancer Res. 2009, 15:3442-3450.
59. Aragones J., et al. Oxygen sensors at the crossroad of metabolism. Cell Metab. 2009, 9:11-22.
60. Milane L., et al. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int. 2011, 11:3.
61. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
62. Ferreira L.M., et al. Metabolic reprogramming of the tumor. Oncogene 2012, 10.1038/onc.2011.576.
63. Facciabene A., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475:226-230.
64. Solomon D.A., et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011, 333:1039-1043.
65. Sheltzer J.M., et al. Aneuploidy drives genomic instability in yeast. Science 2011, 333:1026-1030.
66. Werbowetski-Ogilvie T.E., et al. Evidence for the transmission of neoplastic properties from transformed to normal human stem cells. Oncogene 2011, 30:4632-4644.
67. Klein C.A. Framework models of tumor dormancy from patient-derived observations. Curr. Opin. Genet. Dev. 2011, 21:42-49.
68. Calbo J., et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 2011, 19:244-256.
69. Qian B.Z., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
70. Giannoni E., et al. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox Signal. 2011, 14:2361-2371.
71. Scheel C., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
72. Goel S., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
73. Madsen C.D., Sahai E. Cancer dissemination - lessons from leukocytes. Dev. Cell 2010, 19:13-26.
74. Campbell P.J., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
75. Guo Y., et al. Medusa structure of the gene regulatory network: dominance of transcription factors in cancer subtype classification. Exp. Biol. Med. (Maywood) 2011, 236:628-636.